Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.

Kim JE, Jin DH, Lee WJ, Hur D, Wu TC, Kim D.

Pharmacol Res. 2013 May;71:23-33. doi: 10.1016/j.phrs.2013.02.001. Epub 2013 Feb 18.

2.

Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.

Tseng CW, Monie A, Wu CY, Huang B, Wang MC, Hung CF, Wu TC.

J Mol Med (Berl). 2008 Aug;86(8):899-908. doi: 10.1007/s00109-008-0370-y. Epub 2008 Jun 10.

3.

Immune mechanism of the antitumor effects generated by bortezomib.

Chang CL, Hsu YT, Wu CC, Yang YC, Wang C, Wu TC, Hung CF.

J Immunol. 2012 Sep 15;189(6):3209-20. doi: 10.4049/jimmunol.1103826. Epub 2012 Aug 15.

4.
5.

Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.

Jung SH, Lee YK, Lee HJ, Choi NR, Vo MC, Hoang MD, Lim MS, Nguyen-Pham TN, Kim HJ, Lee JJ.

Exp Hematol. 2014 Apr;42(4):274-81. doi: 10.1016/j.exphem.2013.12.008. Epub 2014 Jan 7.

PMID:
24407159
6.

Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.

Lee SY, Huang Z, Kang TH, Soong RS, Knoff J, Axenfeld E, Wang C, Alvarez RD, Chen CS, Hung CF, Wu TC.

J Mol Med (Berl). 2013 Oct;91(10):1221-31. doi: 10.1007/s00109-013-1054-9. Epub 2013 May 29.

7.

Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.

Cheng WF, Lee CN, Chang MC, Su YN, Chen CA, Hsieh CY.

Mol Ther. 2005 Nov;12(5):960-8. Epub 2005 Jun 24.

PMID:
15979942
8.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
9.

DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.

Kim D, Hung CF, Wu TC, Park YM.

Vaccine. 2010 Oct 21;28(45):7297-305. doi: 10.1016/j.vaccine.2010.08.079. Epub 2010 Sep 17.

10.

Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.

Zeng Q, Peng S, Monie A, Yang M, Pang X, Hung CF, Wu TC.

Hum Gene Ther. 2011 Jul;22(7):809-19. doi: 10.1089/hum.2010.071. Epub 2011 Mar 9.

11.
12.

Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.

Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, Hung CF, Wu TC.

Gene Ther. 2008 Aug;15(16):1156-66. doi: 10.1038/gt.2008.53. Epub 2008 Apr 10.

13.

Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.

Kim JH, Kang TH, Noh KH, Bae HC, Kim SH, Yoo YD, Seong SY, Kim TW.

Immunol Lett. 2009 Jan 29;122(1):58-67. doi: 10.1016/j.imlet.2008.12.006. Epub 2009 Jan 9.

PMID:
19135479
14.

Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.

Moeller I, Spagnoli GC, Finke J, Veelken H, Houet L.

Cancer Immunol Immunother. 2012 Nov;61(11):2079-90. doi: 10.1007/s00262-012-1272-y. Epub 2012 May 6.

PMID:
22562379
15.

Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.

Iwata-Kajihara T, Sumimoto H, Kawamura N, Ueda R, Takahashi T, Mizuguchi H, Miyagishi M, Takeda K, Kawakami Y.

J Immunol. 2011 Jul 1;187(1):27-36. doi: 10.4049/jimmunol.1002067. Epub 2011 Jun 1.

16.

Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency.

Kim JH, Kang TH, Noh KH, Bae HC, Ahn YH, Lee YH, Choi EY, Chun KH, Lee SJ, Kim TW.

Clin Exp Immunol. 2011 Aug;165(2):180-9. doi: 10.1111/j.1365-2249.2011.04410.x. Epub 2011 May 18.

17.
18.

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. doi: 10.1128/JVI.02443-08. Epub 2009 Apr 22.

19.

Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.

Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M.

Cancer Immunol Immunother. 2014 Apr;63(4):321-33. doi: 10.1007/s00262-013-1510-y. Epub 2014 Jan 3.

PMID:
24384835
20.

Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.

Song MY, Park SH, Nam HJ, Choi DH, Sung YC.

J Immunother. 2011 Apr;34(3):297-306. doi: 10.1097/CJI.0b013e318210ed0e.

PMID:
21389868
Items per page

Supplemental Content

Write to the Help Desk